What Purdue Pharma may have known about an OxyContin ring in L.A.

A Los Angeles Times investigation alleges Purdue Pharma, the maker of OxyContin, continued supplying clinics and pharmacies it suspected of trafficking the highly addictive drug and never alerted law enforcement.

In one case, it continued supplying a single doctor clinic that, in just four months, prescribed 73,000 pills—which have a street value of more than $6 million.

To read more about the investigation, and why Purdue feels it was justified in not alerting federal agents, click on the link below:  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”